Get the Stockscreener App
9.73
1.22%
-0.12
After Hours:
9.80
0.07
+0.72%
Benitec Biopharma Inc stock is traded at $9.73, with a volume of 23,337.
It is down -1.22% in the last 24 hours and down -11.46% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$9.85
Open:
$9.86
24h Volume:
23,337
Relative Volume:
0.73
Market Cap:
$225.20M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-0.5743
EPS:
-16.9418
Net Cash Flow:
$-18.07M
1W Performance:
-8.72%
1M Performance:
-11.46%
6M Performance:
+7.87%
1Y Performance:
+205.97%
1-Day Range:
$9.70
$9.9797
1-Week Range:
$9.70
$10.60
52-Week Range:
$2.69
$12.89
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
9.73 | 225.20M | 59,000 | -21.81M | -18.07M | -16.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - GlobeNewswire
Benitec Biopharma to Present at Major Healthcare Conferences in December | BNTC Stock News - StockTitan
Suvretta Capital Management's Strategic Acquisition in Benitec B - GuruFocus.com
How To Trade (BNTC) - Stock Traders Daily
Simplify Asset Management Inc. Increases Position in Benitec Biopharma Inc. (NASDAQ:BNTC) - MarketBeat
Benitec Biopharma Inc reports results for the quarter ended September 30Earnings Summary - XM
Benitec Biopharma Inc. (BNTC) Quarterly 10-Q Report - Quartzy
Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Be - GuruFocus.com
Benitec Biopharma executives receive performance bonuses - Investing.com
Benitec Biopharma Awards Bonuses to Key Executives - TipRanks
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - The Manila Times
Benitec's BB-301 Shows Major Clinical Gains: 35-40% OPMD Symptom Improvement | BNTC Stock News - StockTitan
Benitec Biopharma Inc. (NASDAQ:BNTC) Short Interest Update - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $22.60 Average Target Price from Analysts - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Average Recommendation of “Buy” from Analysts - Defense World
(BNTC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - GlobeNewswire
Long Term Trading Analysis for (BNTC) - Stock Traders Daily
Piper Sandler Initiates Coverage of Benitec Biopharma (BNTC) with Overweight Recommendation - MSN
Janus Henderson Group PLC Expands Investment in Benitec Biopharm - GuruFocus.com
Janus Henderson Group PLC Expands Investment in Benitec Biopharma Inc - Yahoo Finance
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average Price Target from Analysts - Defense World
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts (NASDAQ:BNTC) - Seeking Alpha
Q1 Earnings Estimate for BNTC Issued By Leerink Partnrs - MarketBeat
Benitec started at outperform by Oppenheimer on gene therapy potential (NASDAQ:BNTC) - Seeking Alpha
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average Target Price from Analysts - MarketBeat
Oppenheimer Begins Coverage on Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
JMP Securities Increases Benitec Biopharma (NASDAQ:BNTC) Price Target to $18.00 - Defense World
Benitec Biopharma Reports Promising Results for BB-301 Trial - TipRanks
Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive™
Wells Fargo To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Gene Silencing Market to Expand with Significant CAGR by 2034 |Alnylam Pharmaceuticals, Benitec Biopharma, Arrowhead Pha – IndiaPolitics.com - IndiaPolitics.com
JMP Securities Raises Benitec Biopharma (NASDAQ:BNTC) Price Target to $18.00 - MarketBeat
Piper Sandler maintains Overweight rating on Benitec BioPharma stock By Investing.com - Investing.com UK
Leerink reiterates Benitec BioPharma at Outperform following new BB-301 data - Investing.com Canada
Benitec Biopharma Announces Updated Investor Webcast Information - GlobeNewswire
Global Antisense & RNAi Therapeutics Market Growth in Future - openPR
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase - The Bakersfield Californian
Benitec Biopharma Reports Positive Data from Two Subjects - GlobeNewswire
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society - StockTitan
Costco Wholesale (COST-Q) QuotePress Release - The Globe and Mail
Coinbase Global Inc Cl A (COIN-Q) QuotePress Release - The Globe and Mail
RNAi Therapeutics Market Focusing on Trends and Innovations - openPR
Benitec Biopharma (NASDAQ:BNTC) Stock Price Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Benitec Biopharma's BB-301: Potential In OPMD, But Still Too Early Stages (NASDAQ:BNTC) - Seeking Alpha
Benitec Biopharma Inc. Reports on Recent Stockholder Activity - MarketBeat
Benitec Biopharma issues shares after warrant exercises By Investing.com - Investing.com South Africa
Benitec Biopharma issues shares after warrant exercises - Investing.com India
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
When the Price of (BNTC) Talks, People Listen - Stock Traders Daily
Fresh Study Reveals the Duchenne Muscular Dystrophy Market Insights, Demand, and Forecast to 2033 - WhaTech
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):